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Lipopolysaccharide (LPS) induced pulmonary neutrophil recruitment and 
platelet activation is mediated via the P2Y1 and P2Y14 receptors in mice. 
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Platelet activation occurs during host defence and in various inflammatory disorders. In 
animal models of infection and inflammation, experimental depletion of platelets leads to 
significantly reduced leukocyte recruitment and impaired clearance of pathogens from the 
lung. It is now appreciated that purinergic receptor activation is required for leukocyte 
activation, motility and adhesion, and platelet interactions with leukocytes can be modulated 
by purinergic stimulation of platelets. Here, we have investigated the role of platelet P2Y1, 
P2Y12, P2Y14, and P2X1  receptors on leukocyte recruitment and chemotaxis.  
Mice were administered either vehicle controls or selective P2Y1, P2Y12, P2Y14, or P2X1 
antagonists intravenously before intranasal administration of lipopolysaccharide (LPS) to 
investigate the effect of these drugs on pulmonary leukocyte recruitment, peripheral platelet 
counts, bleeding times, and ex vivo platelet aggregation. Separately, platelets were incubated 
with P2Y1, P2Y12, P2X1 antagonists, or P2Y14 agonists to assess effects on platelet-induced 
neutrophil chemotaxis in vitro. 
Pulmonary neutrophil recruitment induced by intranasal LPS administration was inhibited in 
mice administered either with P2Y1 or P2Y14 antagonists, but not with P2Y12 or P2X1 
antagonists. Furthermore, the administration of either a P2Y1 or a P2Y14 antagonist reversed 
the incidence of peripheral thrombocytopaenia associated with LPS exposure. Bleeding times 
were significantly increased in mice administered P2Y1, P2Y12, or P2X1 antagonists, whilst ex 
vivo platelet aggregation to ADP was significantly reduced. These haemostatic responses 
remained unaltered following antagonism of P2Y14. In vitro chemotaxis assays revealed direct 
antagonism of platelet P2Y1, but not P2Y12 or P2X1 receptors suppressed platelet-dependent 
neutrophil motility towards MDC. Furthermore, the stimulation of platelets with selective 
P2Y14 agonists (UDP-glucose, MRS2690) resulted in significant platelet-dependent neutrophil 
chemotaxis. 
These results reveal a role for P2Y1 and P2Y14 activation of platelets following exposure to LPS, 
whilst haemostatic indices were unaffected by inhibition of platelet function with the P2Y14 





































Platelet activation has been described in patients with chronic obstructive pulmonary disease 
(COPD), acute lung injury (ALI), Inflammatory bowel disease (IBS), rheumatoid arthritis (RA), 
asthma and allergies, and in patients suffering from infectious diseases [1–10]. A number in 
vivo studies have previously demonstrated the presence of platelet activation through the 
upregulation of P-selectin expression, the formation of platelet-leukocyte conjugates and the 
release of pro-inflammatory mediators in septic, allergic, and sterile inflammation. These 
studies also demonstrate the importance of platelets for leukocyte recruitment [3,11–14].  
 
The role of platelet purinergic receptors in the context of platelet aggregation has been well 
documented with co-stimulation of the P2Y1 and P2Y12 receptors by ADP, and following ATP 
stimulation of the P2X1 receptor [15–22]. Furthermore, a number of studies have detailed the 
ability of purinergic receptor stimulation to induce increases in P-selectin expression and the 
incidence of platelet-leukocyte conjugates which are considered to be a prerequisite for 
leukocyte recruitment[23–25]. Using a murine model of allergic airway inflammation we have 
previously demonstrated that pulmonary leukocyte recruitment was mediated via RhoA 
signalling downstream of the platelet P2Y1 receptor, whilst the P2Y12 and P2X1 receptors 
showed no involvement in this process [26]. More recently, platelets have been shown to 
express the P2Y14 receptor on their surface [27]. However, the P2Y14 receptor appears to be 
redundant in platelet aggregation, whilst demonstrating an ability to mediate cell migration 
in other cell types [27–30].  A physiological role for platelet P2Y14 receptor activation therefore 
remains unknown in the context of host defence and inflammation. The aim of the present 
study was therefore to characterise the role of the P2Y1, P2Y12, P2Y14 and P2X1 receptors in a 
murine model of LPS induced pulmonary inflammation which we and others have reported 




PGE1, lipopolysaccharide (LPS, extracted from Escherichia Coli O55:B5 serotype), Ticagrelor 
(1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3H-
[1,2,3] triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol)  and 
adenosine-diphosphate (ADP) were purchased from Sigma (Poole, UK); MRS2179 (N6-methyl-
2’-deoxyadenosine-3’,5’-biphosphate), MRS2500 (2-Iodo-N6-methyl-(N)-methanocarba-2’-
deoxyadenosine-3’,5’-biphosphate), AR-C66096 (2-propylthio-D-β,γ-difluoromethylene ATP), 
NF-279 (8-8'-[Carbonlylbis(imino-4,1-phenylenecarbonylimino-4,1-
phenylenecarbonyliminio)]bis-1,3,5-naphthalenetrisulfonic acid), and MRS2690 
(Diphosphoric acid 1-α-D-glucopyranosyl ester 2-[(4'-methylthio)uridin-5''-yl] ester disodium 
salt) and uridine-di-phosphate glucose (UDP-glucose) from Tocris Bioscience (Bristol, UK). 
Murine MDC from Peprotech (New Jersey, USA); Chemotaxis plates were obtained from 
Neuroprobe (Maryland, USA). 
 
Mouse LPS challenge and bronchoalveolar lavage 
A murine model of LPS induced lung inflammation was established to investigate the 
importance of each of the 4 purinergic receptors expressed on platelets (P2Y1, P2Y12, P2X1 and 
P2Y14) for pulmonary leukocyte recruitment. All studies were carried out under the Animals 
(Scientific Procedures) Act of 1986 (United Kingdom) with local ethical approval of King’s 
College London. Selected groups of female Balb/c mice (8-10 weeks; Harlan UK, Bicester, 
United Kingdom) were treated with MRS2500, AR-C66096, NF-279 (3mg/kg administered 
intravenously), Ticagrelor (3, 10, 30mg/kg administered intra-peritoneally) or PPTN Mesylate 
(10mg/kg administered intravenously), Saline was used as a vehicle for  MRS2500, AR-C66096, 
NF-279 and PPTN Mesylate, 0.1% Dimethyl Sulfoxide was used for Ticragrelor. 20 minutes 
post drug administration, mice were challenged with 1.25mg/kg LPS via intranasal 
administration under isoflurane anaesthetic. 4 hours post LPS challenge, bronchoalveolar 
lavage fluid was collected and processed for total and differential cell counts as previously 
described[11,26,31]. Circulating platelet numbers were enumerated at 4 hours post LPS 
challenge after blood was taken via cardiac puncture, and quantified in stromatol (1:100 




Blood from mice was collected by means of cardiac puncture 1 hour post LPS challenge and 
washed platelets isolated to confirm biological activity and to compare the effects on 
haemostasis of P2Y1, P2Y12, P2Y14 and P2X1 antagonists described above. Platelet aggregation 
was measured after stimulation with 10µmol/L ADP as previously described [26]. Platelet 
aggregation towards UDP-glucose (agonist for P2Y14) was also assessed at increasing 
concentrations to 1µmol/L. 
 
Bleeding times 
Animals were kept under continuous anaesthesia with inhaled isoflurane anaesthetic. 
Bleeding assays were performed 1 hour post LPS challenge in mice by tail tip amputation, 
immersing the tail in saline at 37°C and continuously monitoring bleeding patterns. Each 
animal was monitored for up to 10 minutes and bleeding times determined using a stop clock. 
At the conclusion of the experiment, animals were killed with an overdose of anaesthetic. 
 
 
Platelet-induced leukocyte chemotaxis 
An in vitro assay of platelet-dependent leukocyte chemotaxis was used to elucidate the 
importance of each of the 4 purinergic receptors expressed on platelets on subsequent 
leukocyte activation as previously described [26]. Chemotaxis plates (3µm pore size) were 
blocked with Tyrode’s buffer with 1% BSA for 1 hour. After blocking, the blocking buffer was 
removed and replaced with 100nmol/L macrophage-derived chemokine (MDC). Washed 
platelets at a concentration of 1x108 platelets/ml were prepared from whole blood as 
previously described [26] and were incubated with either the P2Y1, P2Y12 and P2X1 antagonists 
MRS2500, AR-C66096 and NF-279 (1-1000nmol/L) respectively, or the P2Y14 receptor agonists 
UDP-glucose (1-1000nmol/L) or MRS2690 (10-1000nmol/L) for 10 minutes at room 
temperature. Platelets treated with either MRS2500, AR-C66096 and NF-279 were stimulated 
with 100nmol/L ADP for 5 minutes, and then washed. Leukocytes were flushed from bone 
marrow (femurs) of mice and resuspended in a Dulbecco modified Eagle medium based assay 
buffer to a concentration of 5x106 leukocytes/ml.  Leukocytes were then added to platelets 






Data from in vivo animal studies are displayed as means ± SEMs, whilst in vitro chemotaxis 
data are displayed as a chemotactic index. Data were analysed by means of 1-way ANOVA, 





Activation of P2Y1 and P2Y14 but not P2Y12 or P2X1 receptors, is necessary for pulmonary 
leukocyte recruitment in a murine model of LPS induced inflammation  
Exposure to 1.25mg/kg LPS induced a significant increase in total pulmonary leukocyte 
recruitment (P <0.001, Fig 1A) which was accounted for by significant increases in neutrophil 
recruitment (P < 0.001, Fig 1B), and lymphocyte recruitment (P<0.05, Fig 1C). The 
administration of the highly selective and competitive P2Y1 receptor antagonist MRS2500 
(3mg/kg) caused a significant attenuation of LPS induced leukocyte recruitment (P<0.05, Fig 
1A), specifically neutrophil recruitment (P < 0.01, Fig 1B), into the lungs when compared to 
vehicle controls. In contrast, neither administration of the specific P2Y12 antagonist (the 
adenosine triphosphate analogue, AR-C66096) or a P2X1 channel antagonist (the suramin 
analogue, NF-279) were unable to inhibit LPS induced leukocyte recruitment to the lungs (Fig 
1A-C). Administration of the prodrug of a P2Y14 antagonist (PPTN Mesylate)[33] suppressed 
LPS induced leukocyte recruitment (P<0.05, Fig 1A), and specifically neutrophil recruitment 
(P < 0.01, Fig 1B). Lymphocyte recruitment was also reduced by 62%, although this did not 
reach statistical significance (Fig 1C).  
Whilst these data demonstrating an involvement of P2Y1 receptor activation in leukocyte 
recruitment towards LPS is in agreement with previous data we have published in allergic 
inflammation[26], we further investigated P2Y12 antagonism, since this receptor has been 
reported elsewhere to be involved in neutrophil inflammation [34–37]. Mice were 
administered a second P2Y12 antagonist (Ticagrelor). However this did not lead to a 
suppression of pulmonary neutrophil recruitment induced by LPS at 3mg/kg or 10mg/kg 
(LPS+Veh: 30.9±9.8x104 cells/ml, LPS+ 3mg/kg Ticagrelor: 44.9±16.7x104 cells/ml, LPS+ 
10mg/kg Ticagrelor: 35.8±16.7x104 cells/ml). Ticagrelor administration at 30mg/kg however, 
did reduce neutrophil recruitment, but this did not reach statistical significance (30mg/kg: 
12.4±16.7x104 cells/ml). 
Given that P2Y1, P2Y12, P2Y14, and P2X1 receptors are all expressed on platelets, and platelet 
activation is necessary for pulmonary leukocyte recruitment in this model of inflammation 
[12,22,27,38], we further examined the effects of these receptors on platelet dynamics (in 
vivo) and platelet-neutrophil interactions (in vitro). 
 
Peripheral thrombocytopaenia occurs after intranasal instillation with LPS, and this is 
reversed after antagonism of either the P2Y1 or P2Y14 receptors. 
Peripheral thrombocytopaenia occurs during inflammation, perhaps because of localised 
recruitment [38]. Here, the intranasal administration of LPS lead to a significant decrease in 
circulating platelets at 4 hours compared to sham treated control mice (P<0.001, Fig 2). This 
thrombocytopaenia induced by LPS administration was significantly reversed in mice 
administered either the P2Y1 antagonist (P<0.001, Fig 2), or the P2Y14 antagonist (P<0.01, Fig 
2) compared to mice receiving LPS + vehicle. In contrast, the thrombocytopaenia induced by 
LPS remained in mice administered either the P2Y12 antagonist (P<0.001, Fig 2), or the P2X1 
antagonist (P<0.01, Fig 2) compared to sham treated control mice. These data suggested 
platelet activation was modulated by P2Y1 or P2Y14   receptor activation in this model, whereas 
pulmonary neutrophil recruitment is dependent on platelet activation.  
 
Platelet induced-leukocyte migration is mediated by the P2Y1 and P2Y14 receptors in vitro 
P2Y1 and P2Y14 receptors are expressed systemically and are not restricted solely to the 
platelets surface [29,30,39]. We have previously used an in vitro model of platelet-induced 
leukocyte chemotaxis to better understand how platelets taken from allergen-sensitized mice 
and treated with P2Y1 antagonists can modulate leukocyte motility and chemotaxis [26]. In 
non-allergic inflammation, we have used the same assay to assess how platelet P2Y1 or P2Y14 
receptors can mediate leukocyte chemotaxis and correlate with P2Y1 or P2Y14 dependent 
neutrophil recruitment into tissue in response to LPS observed in vivo. Platelets and PMNs 
were isolated from the blood and bone marrow of mice. Platelets were subsequently 
incubated with either the P2Y1 antagonist (MRS2500), P2Y12 antagonist (AR-C66096) or the 
P2X1 antagonist (NF-279) prior to stimulation with 100nM ADP. Following incubation and 
stimulation with drugs or ADP, platelets were subsequently added to PMNs to stimulate their 
chemotaxis with 100nmol/L macrophage derived chemokine (MDC). In agreement with 
previous work [26], only the incubation of platelets with PMNs induced significant chemotaxis 
towards MDC (P < 0.001; Fig 3A, B and C; P < 0.001) compared to negative controls (PMNs 
alone, PMNs with MDC). Pre-incubation with the P2Y12 antagonist AR-C66096 or the P2X1 
antagonist NF-279 failed to modulate platelet induced chemotaxis of PMNs towards MDC (Fig 
3B and 3C), which was in agreement with work previously published by the authors [26]. 
However, pre-incubation of platelets with the P2Y1 antagonist MRS2500 induced a significant 
concentration-dependent inhibition of PMN chemotaxis towards MDC (P < 0.001, Fig 3A). As 
the P2Y14 receptor antagonist (PPTN) is a prodrug and requires metabolism within the liver to 
produce its active form, we investigated whether stimulation of platelets via P2Y14 receptors 
could mimic the ADP (P2Y1) –dependent platelet activation in this assay. Thus, the P2Y14 
agonist UDP-glucose, and a highly specific P2Y14 agonist (MRS2690) were used to stimulate 
the platelet expressed P2Y14. Following incubation and stimulation of platelets with these 
agonists, platelet-induced PMN chemotaxis was induced to MDC (100nmol/L) in a 
concentration dependent manner with 1000nmol/L UDP-glucose (P<0.05; Fig 3D) or 1000nM 
MRS2690 (P<0.05, Fig 3E). Levels of PMN chemotaxis were similar in these conditions to when 
platelets are stimulated with 100nmol/L ADP (P<0.05, Fig 3D & 3E). 
 
Effects of P2Y1, P2Y12, P2Y14 and P2X1 antagonist administration on haemostatic 
measurements in vivo and in vitro. 
Given the inability of either the P2Y12 or P2X1 antagonists to effect leukocyte recruitment in 
response to exposure to LPS, the biological activities of AR-C66096 (P2Y12 antagonist) and NF-
279 (P2X1 antagonist) were assessed by ex vivo platelet aggregation assays, and in vivo 
bleeding time assays. This was done to confirm that the drugs were present at effective doses, 
and to compare with the P2Y1 and P2Y14 antagonists that did supress LPS-induced pulmonary 
leukocyte recruitment. Ex vivo aggregation of platelets from mice administered LPS revealed 
that the possible activation of platelets by LPS had no effect on platelet aggregation towards 
ADP (10µmol/L) per se (Fig 4A & 4B), yet mice administered the P2Y12 antagonist (AR-C66096) 
had a similarly significant reduction in platelet aggregation to those administered the P2Y1 
antagonist (MRS2500) (P<0.05, Fig 4A & 4B). However, we failed to demonstrate any effect 
of the P2X1 antagonist or the P2Y14 antagonist on platelet aggregation towards ADP ex vivo, 
as expected given the stimulus (Fig 4A & 4B). We therefore also investigated the effect of 
these antagonists on in vivo bleeding times. We demonstrated that LPS challenge had no 
effect on bleeding times per se (Fig 4C). Administration of the P2Y1 antagonist (MRS2500), the 
P2Y12 antagonist (AR-C66096) or the P2X1 antagonist (NF-279) demonstrated significant 
prolongation in bleeding time when compared to vehicle controls (P2Y1: P < 0.05, P2Y12: P < 
0.05, P2X1: P < 0.05, Fig 4C) which in addition to the attenuation of ADP induced ex vivo 
platelet activation confirms their biological activity at the tested doses. In contrast, 
administration of 10mg/kg PPTN (P2Y14 antagonist) had no impact on bleeding times when 
compared to vehicle controls (Fig 4C) despite demonstrating attenuation of leukocyte 
recruitment following LPS challenge. Furthermore, whilst the P2Y14 agonist UDP-glucose was 
able to stimulate platelet-induced PMN chemotaxis towards MDC in vitro (1 µmol/L, Fig 3D), 
the same concentration of this drug did not induce platelet aggregation in vitro (Fig 4D), 




In this present study, we have shown that LPS induced pulmonary leukocyte recruitment in 
mice is dependent on P2Y1 receptor activation, in a distinct model to our previous studies 
where we used a murine model of allergic airways inflammation [26]. Whilst this present 
study has revealed that antagonism of P2Y1 receptors led to a suppression of inflammation 
and separately, effects on haemostasis, we have reported an apparent dichotomy in platelet 
P2Y1 signalling in the context of inflammation compared to haemostasis [26,38].  Within the 
context of this study, it is apparent that the intranasal administration of LPS, which induced 
robust platelet dependent pulmonary neutrophil recruitment [12,38], did not affect bleeding 
time, or the magnitude of platelet aggregation in response to ADP ex vivo. These observations 
give further weight to the hypothesis that platelet activation involved in inflammation and 
haemostasis are not necessarily linked [40]. 
 
For the first time, we reveal that P2Y14 receptor activation can affect platelet function by 
stimulating platelet-induced PMN chemotaxis (in vitro), and in the context of platelet-
dependent pulmonary neutrophil recruitment in vivo. However, all measured haemostatic 
parameters were not affected by P2Y14 in vivo. Whilst the role of platelet purinergic receptors 
(P2X1, P2Y1, P2Y12) in platelet aggregation has been well documented, P2Y14 has an unknown 
significance, with various studies suggesting that classical platelet activation is not altered 
[22–25,33].   P2Y14 receptors are coupled to the G protein Gi, and are activated by uridine 
diphosphate (UDP) and UDP-glucose [33]. Currently, signalling downstream of the P2Y14 
receptor remains to be elucidated in platelets. With respect to host defence, activation of 
purinergic receptors also induces selectin and integrin adhesion molecule expression on the 
surface of leukocytes [23,24,32], receptors known to be necessary for leukocyte chemotaxis 
[32,41,42]. Whilst it is not yet known whether P2Y14 has any consequence with regards to 
platelet function (during haemostasis, or inflammation), P2Y14 does promote RhoA-mediated 
signalling and chemotaxis in neutrophils [42]. Platelet shape change, filopodia formation, 
cytoskeletal changes and granule centralization are presumably events required to elicit 
platelet function during inflammatory events; nevertheless a role for Rho-GTPases in purine-
induced platelet activation in the context of host defence is not yet known. 
 
With similarities to our previous work, we were unable to provide evidence for a role for P2Y12 
and P2X1 receptors in the context of LPS-induced inflammation, or P2Y12 and P2X1 dependent 
platelet function with respect to enhancement of neutrophil chemotaxis. We recognise that 
other groups have reported a role for P2Y12 receptors during a model of allergic inflammation 
[34], but this is perhaps contrary to other reports stating that LPS-induced systemic 
inflammation is actually more severe in P2Y12 deficient mice [35], whilst also mediating LPS 
induced inflammation [36]. It is also interesting to note that the P2Y12 antagonist ticagrelor 
may have anti-inflammatory characteristics due to effects on adenosine receptors other than 
P2Y12 [43], and recently this drug has been reported to exhibit antagonism of P2Y13 [39]. Thus, 
the non significant trend depicting inhibition of neutrophil recruitment at the highest dose of 
ticagrelor tested here (30mg/kg) might involve secondary off-target effects on additional 
receptors involved in the inflammatory response, since in both a model of allergic airway 
inflammation and in this present study investigating LPS-induced lung inflammation, no other 
P2Y12 antagonist has displayed any potency as an anti-inflammatory agent [22].  Finally, 
despite our inability to show a role for P2X1 receptors in either allergic or LPS-induced 
inflammation, it should be noted that other groups have separately reported a role for P2X1 
receptor activation in acute inflammatory events [40].  
 
In conclusion, we have demonstrated a role for P2Y1 and P2Y14 receptor activation in a 
platelet-dependent LPS induced model of neutrophil recruitment in the mouse, and that 
these two receptor types stimulate platelet-induced neutrophil chemotaxis in vitro. 
Furthermore, the P2Y14 dependent events did not affect haemostatic measurements, whilst 
P2Y12 and P2X1 receptors expressed on platelets did not modulate LPS-induced inflammation.  
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Figure 1: Effect of antagonism of purinergic receptors that are characteristically expressed 
on platelets on LPS induced lung inflammation. Mice were administered either vehicle, P2Y1, 
P2Y12, P2Y14, or P2X1 antagonists intravenously 20 minutes prior to the instillation of 
1.25mg/kg LPS. 4 hours post challenge, broncho-alveolar lavages (BAL) were performed for 
the enumeration of total leukocytes counts (A); neutrophils (B); and lymphocytes (C). Data: 
means ± SEM. n= 8-15 per group. *** P <0.001 vs sham+ vehicle, # P <0.05 vs LPS + vehicle, 
## P<0.01 vs LPS + vehicle. 
 
Figure 2: Effect of LPS and purinergic receptor antagonists on circulating peripheral platelet 
numbers. Mice were administered either vehicle, P2Y1, P2Y12, P2Y14, or P2X1 antagonists 
intravenously 20 minutes prior to the instillation of 1.25mg/kg LPS. 4 hours later, blood 
samples were taken via cardiac puncture for the enumeration of circulating platelet counts. 
Data: means ± SEM. n= 4-8 per group. ** P <0.01 vs sham+ vehicle, *** P <0.001 vs sham+ 
vehicle,  ## P <0.01 vs LPS + vehicle, ### P<0.001 vs LPS + vehicle. 
 
Figure 3: Effect of P2Y1, P2Y12, P2Y14 and P2X1 on platelet-induced PMN chemotaxis. 
Platelets were isolated from mouse blood and leukocytes collected from femoral bone 
marrow. Platelets were treated with the P2Y1 antagonist (MRS2500) (A), the P2Y12 antagonist 
(AR-C66096) (B), or the P2X1 antagonist (NF-279) (C), or UDP-glucose (P2Y1 agonist) (D), or 
MRS2690 (P2Y1 agonist) (E); and washed before being mixed with leukocytes. This cell mixture 
was added to the top well of a chemotaxis chamber consisting of 3µm pores. PMN chemotaxis 
towards MDC (bottom well 100nmol/L) was then quantified after a 90 minute incubation and 
analysed as a chemotactic index. n=8 (A), 7 (B), 4 (C), 3 (D), 4 (E). Data are expressed as mean± 
SEM.  * P < 0.05,  *** P < 0.001 vs column 3 (or 1 for D & E), or # P < 0.05, ### P < 0.01 vs 
positive control (black column). 
 
Figure 4: Effect of purinergic receptor antagonism on haemostatic responses and platelet 
aggregation. Mice were administered either vehicle, P2Y1, P2Y12, P2Y14, or P2X1 antagonists 
intravenously 20 minutes prior to the instillation of 1.25mg/kg LPS. 1hour post challenge, 
blood samples were collected via cardiac puncture to assess platelet aggregation towards 
10µmol/L ADP ex vivo. An example aggregation trace is shown (A), and group % aggregation 
(B). In other experiments, bleeding time was assessed in anaesthetised mice at 1 hour post 
LPS challenge (C). In separate experiments, cardiac bleeds were undertaken from naive mice 
and platelets harvested for assessment of aggregation to ADP and UDP-glucose (D)  Data: 
means ± SEM. n= 4 (B), 3-4 (C), 4 (D). * P <0.01 vs LPS+ vehicle (white column in D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
